Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | VCP | P55072 | 8/20 | 0.39 |
| ▸ | STK4 | Q13043 | 1/20 | 0.37 |
| ▸ | STK3 | Q13188 | 1/20 | 0.37 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.34 |
| ▸ | PIM1 | P11309 | 3/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.32 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyprazepam SCHEMBL30736035 | 1.00 | CYP1A2 (0.56) | CYP1A2KDM4EVCPSTK4STK3 | |
| Cyprazepam SCHEMBL29040984 | 0.99 | CYP1A2 (0.56) | CYP1A2KDM4EVCPSTK4STK3 | |
| Cyprazepam SCHEMBL8350722 | 0.89 | CYP1A2 (0.53) | CYP1A2KDM4EVCPSTK4STK3 | |
| SCHEMBL28910535 | 0.86 | CYP1A2 (0.59) | CYP1A2KDM4E | |
| Cyprazepam SCHEMBL8318567 | 0.83 | CYP1A2 (0.46) | CYP1A2KDM4ECHRM1 | |
| SCHEMBL7308839 | 0.83 | CYP1A2 (0.56) | CYP1A2KDM4E | |
| Hydrochloric Acid SCHEMBL11742135 | 0.83 | CYP1A2 (0.56) | CYP1A2KDM4E | |
| Hydrochloric Acid SCHEMBL11746684 | 0.82 | CYP1A2 (0.56) | CYP1A2KDM4E | |
| SCHEMBL11435562 | 0.82 | CYP1A2 (0.57) | CYP1A2KDM4ECHRM1 | |
| Chlordiazepoxide SCHEMBL29358041 | 0.82 | CYP1A2 (0.60) | CYP1A2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2467 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238250-A1 | METHOD OF USING PIROMELATINE FOR TREATING PARASOMNIAS ASSOCIATED WITH LOSS OF REM SLEEP ATONIA | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2024-07-18 | — | — | US | claimed |
| WO-2024150170-A1 | PIROMELATINE FOR TREATING PARASOMNIAS ASSOCIATED WITH LOSS OF REM SLEEP ATONIA | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2024-07-18 | — | — | WO | claimed |
| US-10689373-B2 | 1,2-substituted cyclopentanes as orexin receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-06-23 | — | — | US | claimed |
| US-20190275048-A1 | METHOD OF TREATING INSOMNIA | ROSENBERG LEON I (US) | 2019-09-12 | — | — | US | claimed |
| US-20180282309-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-04 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-8735383-B2 | Glycine transporter-1 inhibitors | AMGEN INC. (US) | 2014-05-27 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20120195985-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | AMGEN INC. (US) | 2012-08-02 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-1599199-A2 | METHODS FOR TREATING JOINT PAIN OR IMPROVING SLEEP USING AN ESTROGEN AGONIST/ANTAGONIST | Pfizer Products Inc. (US) | 2005-11-30 | — | — | EP | claimed |
| US-20040152713-A1 | Methods for treating joint pain or improving sleep using an estrogen agonist/antagonist | PFIZER INC. | 2004-08-05 | — | — | US | claimed |
| WO-2004064832-A2 | METHODS FOR TREATING JOINT PAIN OR IMPROVING SLEEP USING AN ESTROGEN AGONIST/ANTAGONIST | PFIZER PRODUCTS INC. (US) | 2004-08-05 | — | — | WO | claimed |
| JP-2000511885-A | — | — | 2000-09-12 | — | — | JP | claimed |
| EP-0900086-A4 | ENHANCEMENT OF SLEEP WITH A GROWTH HORMONE SECRETAGOGUE | MERCK & CO INC (US) | 2000-01-12 | — | — | EP | claimed |
| EP-0900086-A1 | ENHANCEMENT OF SLEEP WITH A GROWTH HORMONE SECRETAGOGUE | Merck & Co., Inc. (US) | 1999-03-10 | — | — | EP | claimed |
| WO-1997041879-A1 | ENHANCEMENT OF SLEEP WITH A GROWTH HORMONE SECRETAGOGUE | MERCK & CO., INC. (US) | 1997-11-13 | — | — | WO | claimed |